
    
      Participants were equally randomized to either one of 4 treatment arms or a placebo arm. The
      trial consists of a Screening period lasting up to 42 days, a two-year double-blind
      placebo-controlled (DBPC) treatment phase, which begins at randomization (Week 0) and ends at
      Year 2, and a 3-year extended follow-up phase.
    
  